Experts assume that more than 50 percent of Americans over the age of 50 have had symptoms related to hemorrhoidal disease at some point in their lives(1).

Nycomed's 2010 performance continued to show above industry average growth in emerging markets, as well as strong growth of Key Products (excluding pantoprazole), Regional and Local prescription (Rx) drugs.

Roche's Annual General Meeting, which was held in Basel, has approved all of the Board of Directors' proposals. The 818 shareholders in attendance, representing 142,963,212 or 89.4% of a total of 160,000,000 bearer shares, approved the 2010 Annual Report and financial statements.

Nycomed's US partner Forest Laboratories, Inc. (NYSE: FRX) announced that DalirespTM (roflumilast) was approved by the US Food and Drug Administration (FDA) as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations

Genzyme Corporation (NASDAQ: GENZ) recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards (PAL Awards).

Amgen (Nasdaq: AMGN) announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA(TM) (denosumab) to Zometa(R) (zoledronic acid) in preventing bone complications called skeletal-related events (SREs) in 1,901 men with prostate cancer and bone metastases.

Bayer HealthCare and Onyx Pharmaceuticals, Inc. announced that the companies have begun enrolling patients in a Phase III randomized, double-blind, placebo-controlled trial evaluating Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.